Key Facts

IndustryPharmaceutical Contract Developer and Contract Manufacturer (CDMO)
Business ModelDevelopment and production of pharmaceutical products on behalf of customers , as well as the development, production and sales of own products.
Turnoverca. 20 million euros p/a
Staff complement140
Acquisition dateOctober 2013
Fund advised by DUBAGLenbach Equity Opportunities I. SCSp
ExitThe company was divested to Daicel corporation in August 2018

Operational Details

  1. Successful implementation of a sales department
  2. Missing structures were created and new positions were filled
  3. Expansion of the existing customer base
  4. Significant reduction of financial liabilities
  5. Reintroduction of „own“ products
  6. Significant increase in sales and earnings

Further Case Studies